Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 8Phase 3 5Phase 1/2 4

Status

Recruiting 3Active not recruiting 2

Sponsor Class

NIH 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Fallopian Tube Neoplasms 4Brenner Tumor 4Colorectal Neoplasms 3Colonic Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Tongue Neoplasms 1Stroke 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Lymphoid Interstitial Pneumonia 1Kidney Failure, Chronic 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Endometrial Neoplasms 1Diabetes Mellitus 1Coronary Artery Disease 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 66Cisplatin 57Paclitaxel 42Radiotherapy 35Pemetrexed 34Gemcitabine 31Docetaxel 31Etoposide 24pembrolizumab 21Vinorelbine 20Erlotinib Hydrochloride 13Magnetic Resonance Spectroscopy 12Gefitinib 11Specimen Handling 10Radiosurgery 10Drug Therapy 10Bevacizumab 10durvalumab 9Nivolumab 9Vinblastine 6Topotecan 6Surgical Procedures, Operative 6Cyclophosphamide 6Standard of Care 5Platinum 5Immunoglobulin G 5Ifosfamide 5Disulfides 5Dexamethasone 5paclitaxel poliglumex 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Lung Neoplasms × Disulfides × Clear all
NCT06498635 2026-05-27

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

National Cancer Institute (NCI)

Phase 3 Recruiting
306 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04181060 2026-05-18

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
300 enrolled
Thoracic

Lung Neoplasms

NCT06732401 2026-05-13

CLEAR

National Cancer Institute (NCI)

Phase 3 Active not recruiting
630 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05624996 2026-05-04

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

NRG Oncology

Phase 3 Recruiting
474 enrolled
Thoracic

Lung Neoplasms

NCT04092283 2026-05-01

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
660 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡